Compare Abeona Therapeutics Inc (ABEO) vs CAVA Group Inc (CAVA) Price & Performance

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

CAVA stock is trading at $71.91, down 6.46% with a bearish technical signal. The company shows strong revenue growth reaching $1.18 billion in 2025 with positive net income of $63.74 million, though valuation metrics remain elevated with a P/E of 138.29. Recent earnings beat expectations in Q1 2026 with $0.20 EPS versus $0.17 expected. Analyst sentiment remains strongly positive with 72% buy ratings and a $94.19 consensus price target, representing 31% upside potential from current levels.

The outlook remains favorable given CAVA's expansion trajectory and market share gains in the fast-casual segment, though high valuation multiples and margin pressures present risks. The stock's recent pullback offers potential entry point for growth investors, but requires monitoring of same-store sales trends and competitive dynamics in the restaurant industry.